Royalty Report: Drugs, Blood Clotting, Technical Know How – Collection: 291124

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Blood Clotting
  • Technical Know How
  • cardiac
  • Wound Care
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 291124

License Grant
The Licensor of Belgium grants under the Licensor Patents and Licensor Know-how an irrevocable, worldwide license, with right to sublicense to the Secondary Source and the Back-up Secondary Source, to develop, use for regulatory or legal purposes, sell, have sold, and either manufacture if Licensee is the secondary source and/or Back-up secondary source, or have manufactured by the Secondary Source and/or Back-up Secondary Source.

Licensor shall not engage in, or enable any third party to engage in, any commercialization, licensing, manufacturing, marketing or sales activity with respect to the application of Licensor Know-how or the Licensed Process to Integrelin with or on behalf of any third party without Licensees prior written consent.  This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor has developed a unique and valuable patented and proprietary process useful for the manufacture of bulk peptide products containing Integrelin(TM)

Licensee owns certain patent rights, trademarks and know-how relating to a product called Integrelin(TM).

Bulk Product shall mean a bulk peptide product which contains Integrelin, is produced by the Licensed Process and is intended to undergo further processing, formulation and/or vialing and packaging.

Integrelin shall mean a specific peptide designated by Licensee and known as Integrelin(TM),

Field of Use
Integrilin (eptifibatide) helps to prevent platelets in your blood from sticking together and forming a blood clot.

IPSCIO Record ID: 282942

License Grant
Licensee agrees to purchase from Belgian Licensor and Licensor agrees to manufacture and supply to Licensee an amount of Bulk Product through Purchase Orders.
License Property
Bulk Product shall mean a bulk peptide product which contains eptifibatide, is produced by the Licensed Process (as defined in the License Agreement) and is intended to undergo further processing, formulation and/or vialing and packaging.

Eptifibatide shall refer to a specific peptide designated by Licensee and known as eptifibatide, which same peptide was known previously as Integrilin or Integrelin, the chemical structure of which is known to Licensor because of the prior business relationship between Licensee and Licensor.

Field of Use
Eptifibatide (Integrilin) is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.

Integrilin is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries).

IPSCIO Record ID: 372507

License Grant
The Licensor of Belgium shall grant a nonexclusive and non-transferable right to grant to the Secondary Source a sole, worldwide and non-transferable sublicense, without right to grant further sublicenses, under
— the Licensor Patents, and the Licensor Know How, existing on the Secondary Source Effective Date, and any patents, including inventors certificates, applications, substitutions, extensions, reissues, re-examinations, renewals, divisions, continuations or continuations-in-part derived from such License Patents or which claim such Solvay Know-How, whenever issued, and
— any License Improvement existing on the Secondary Source Effective Date, for the sole purpose of manufacturing, producing and supplying, and performing development activities related thereto, to Licensee and to any Licensee Affiliate or Sublicensee, the Bulk Drug Substance, and/or drug product containing, or made using, the Bulk Drug Substance, whether in finished, partially finished or bulk form.
License Property
Licensor has performed certain development activities with respect to omiganan pentahydrochloride, and has in particular been working to develop a commercial process for the production of the same.

Secondary Source is for the production of Bulk Drug Substance through the Licensed Process, and supply of the same to Licensee, its Affiliates and Sublicensees.

Omiganan Drug Substance shall mean any bulk peptide product that contains omiganan pentahydrochloride.

Field of Use
Omigard(TM) (omiganan pentahydrochloride 1% topical gel) is for the prevention of catheter-related infections.

The product is used for certain indications, including the topical administration to a burn site or a surgical wound site for the treatment or prevention in humans of burn-related or surgery-related infections; and the topical administration to a device or the site around the device for the treatment or prevention in humans of device-related infections, including local catheter site infection and catheter related blood stream infection.

The Letter of intent would perform certain development studies on omiganan pentahydrochloride, and further develop a commercial process for the production of the same, and would supply commercial quantities of omiganan pentahydrochloride to Licensee.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.